Identification/NN
of/IN
sequence/NN
alterations/NNS
in/IN
the/DT
upstream/JJ
regulatory/JJ
region/NN
of/IN
the/DT
estrogen/NN
receptor/NN
gene/NN
in/IN
an/DT
ER-negative/JJ
breast/NN
cancer/NN
cell/NN
line/NN
./.

Given/IN
the/DT
important/JJ
role/NN
of/IN
the/DT
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
in/IN
the/DT
development/NN
and/CC
physiology/NN
of/IN
the/DT
breast/NN
,/,
it/PRP
is/VBZ
essential/JJ
to/TO
delineate/VB
the/DT
mechanisms/NNS
responsible/JJ
for/IN
its/PRP$
failed/JJ
expression/NN
in/IN
some/DT
breast/NN
tumors/NNS
./.
=====
We/PRP
have/VBP
cloned/VBN
and/CC
sequenced/VBN
a/DT
portion/NN
of/IN
the/DT
ER/NN
upstream/JJ
regulatory/JJ
region/NN
from/IN
the/DT
ER-positive/JJ
MCF-7/NN
and/CC
the/DT
ER-negative/JJ
MDA-MB-231/NN
breast/NN
cancer/NN
cell/NN
lines/NNS
to/TO
determine/VB
if/IN
sequence/NN
alterations/NNS
in/IN
this/DT
region/NN
account/VBP
for/IN
the/DT
ER-negative/JJ
phenotype/NN
of/IN
some/DT
tumors/NNS
./.
=====
From/IN
this/DT
,/,
we/PRP
identified/VBD
a/DT
number/NN
of/IN
variations/NNS
between/IN
the/DT
sequences/NNS
,/,
two/CD
of/IN
which/WDT
were/VBD
determined/VBN
to/TO
be/VB
associated/VBN
with/IN
a/DT
50/CD
%/NN
decrease/NN
in/IN
CAT/NN
activity/NN
./.